US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
ドイツ
TG
Sernova Biotherapeutics Inc (PSH0) 銘柄情報

Sernova Biotherapeutics Inc (PSH0)

0.0906

0.00

( 0.00% )

更新日時： 14:08:16

Sernova Biotherapeutics Inc (PSH0) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.0906

( - )

買値

0.0912

売値

0.0946

出来高

0.00

0.00 日の範囲 0.00

0.073 52 週間の範囲 0.139

時価総額

前日終値

0.0906

始値

-

時刻

最終取引時間

-

財務取引量

-

VWAP

-

平均取引量 (3 か月)

117,360 €

発行済株式数

377,000,009

配当利回り

PER

-4.08

1 株当たり利益 (EPS)

-0.04

歳入

-

純利益

-11.91M

Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longe... Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc is based in Mississauga, Canada. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.sernova.com

本社

Mississauga, Canada

設立

-

Sernova Biotherapeutics Inc is listed in the sector of the Tradegate (DE) with ticker PSH0. The last closing price for Sernova Biotherapeutics was 0.09 €. Over the last year, Sernova Biotherapeutics shares have traded in a share price range of 0.073 € to 0.139 €.

Sernova Biotherapeutics currently has 377,000,009 shares in issue. The market capitalisation of Sernova Biotherapeutics is 34.16 € million. Sernova Biotherapeutics has a price to earnings ratio (PE ratio) of -4.08.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.0048	-5.03144654088	0.0954	0.0984	0.0854	16872	0.08922059	DE
4	-0.004	-4.22832980973	0.0946	0.103	0.0854	35626	0.09388822	DE
12	-0.0134	-12.8846153846	0.104	0.1185	0.0854	51633	0.10258798	DE
26	0.0091	11.1656441718	0.0815	0.1185	0.074	61302	0.09679325	DE
52	-0.0104	-10.297029703	0.101	0.139	0.073	61920	0.10025952	DE
156	-0.0479	-34.5848375451	0.1385	0.153	0.073	59664	0.10472605	DE
260	-0.0479	-34.5848375451	0.1385	0.153	0.073	59664	0.10472605	DE

PSH0 - Frequently Asked Questions (FAQ)

What is the current Sernova Biotherapeutics Inc share price?

The current share price of Sernova Biotherapeutics Inc is 0.0906 €

How many Sernova Biotherapeutics Inc shares are in issue?

Sernova Biotherapeutics Inc has 377,000,009 shares in issue

What is the market cap of Sernova Biotherapeutics Inc?

The market capitalisation of Sernova Biotherapeutics Inc is EUR 34.16M

What is the 1 year trading range for Sernova Biotherapeutics Inc share price?

Sernova Biotherapeutics Inc has traded in the range of 0.073 € to 0.139 € during the past year

What is the PE ratio of Sernova Biotherapeutics Inc?

The price to earnings ratio of Sernova Biotherapeutics Inc is -4.08

What is the registered address of Sernova Biotherapeutics Inc?

The registered address for Sernova Biotherapeutics Inc is RPO Central Parkway, Mississauga, Ontario, L5A 4H2

What is the Sernova Biotherapeutics Inc website address?

The website address for Sernova Biotherapeutics Inc is www.sernova.com

US Market News

US Market News 2分前

KBR Launches Inaugural Innovation Studio Powered by Applied Computing in BengaluruJune 16, 2026 3:35 AM
PR Newswire (US) class="legendSpanClass"BENGALURU, India, class="legendSpanClass"June 16, 2026 /PRNewswire/ -- KBR (NYSE: KBR) launch

tkg

I don't see any end in sight for the insatiable demand for compute and data centers, to the contrary, demand is going parabolic.

Qualcomm CEO says AI agents will replace apps — as chip giant works on 40 new AI-powered devices
PUBLISHED TUE, JUN 16 20261:08 AM EDT

knrorrel

knrorrel 4分前

GPUS Everyone should keep an eye on this one; GPUS should continue to rise over the coming days and weeks. And once a deal is announced, the stock’s real future should truly take off—driven by strong revenue and massive profits. imho ,🚀 https://investorshub.advfn.com/boards/read_msg.aspx?me

silattore

silattore 4分前

WOW! Umpteenth dilution. Another umpteenth times to go. Well done.
Didn't know being a CEO and managing a company is this easy, as far as AMC is concerned. You earn money or lose money, doesn't matter. There is always dilution.

If retail shareholders oppose another dilution, t

knrorrel

knrorrel 5分前

GPUS
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177706706

knrorrel

knrorrel 5分前

GPUS Everyone should keep an eye on this one; GPUS should continue to rise over the coming days and weeks. And once a deal is announced, the stock’s real future should truly take off—driven by strong revenue and massive profits. imho ,🚀 https://investorshub.advfn.com/boards/read_msg.aspx?me

CelestialSage6

CelestialSage6 16分前

Yes, I understand. Even if you combine all of that, can it beat Dupixent? Alteogen only collaborates with the best companies. On the other hand, Halozyme has signed contracts with companies that I don't even know if they are actually working with. So, it's not Alteogen signing with junk, but Halozym

CA Market News

CA Market News 17分前

Herbal Dispatch Provides Update on Domestic Retail Operations and Proprietary Brand ExpansionJune 16, 2026 3:01 AM
NewsfileVancouver, B

tkg

The Strategic Verdict

This Forbes article is a massive structural validation for long-term Lightwave shareholders. For years, the bears argued that Lightwave was a standalone science project trying to force its way into the market.

Now, the U.S. government and GlobalFou

Hellie

Hellie 25分前

11/06 , maybe you're right!

biotechinvestor1

biotechinvestor1 28分前

Here are a few of those drugs:
Ebglyss (IL-13)Adbry (IL-13)Nemluvio (IL-31 receptor)Late-stage agents such as zumilokibart.

Henk van vleuten

Henk van vleuten 29分前

When was it publiced? Maybe this why on 12june there was a huge spike on Jan 2027 15 options??

biotechinvestor1

biotechinvestor1 30分前

You ate wrong again! Not all Halozyme targets are public info for obvious competitive reasons.
There are number of other drugs in the class of Dupixent that halozyme might have an exclusive non-disclosed contract for. Here are a few of those drugs:

God Bless America

God Bless America 31分前

Of course they did not buy because they knew the regulation. Their families did buy instead.

US Market News

US Market News 31分前

Uxin Reports Unaudited Financial Results for the Quarter Ended March 31, 2026June 16, 2026 3:00 AM
PR Newswire (US) class="legendSpanClass"BEIJING, class="legendSpanClass"June 16, 2026 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company

US Market News

US Market News 31分前

DXC Expands Relationship with Norske Skog to Modernize Network and Technology OperationsJune 16, 2026 3:00 AM
PR Newswire (US) Multi-year partnership delivers a modern, secure network solution while broadening DXC's role across Norske Sko

US Market News

US Market News 32分前

Solidion Technology Announced AI-Assisted Design and Manufacturing Technology of Bipolar Solid-State Batteries for Space Vehicles, Ground, Sea, Air and InfrastructureJune 16, 2026 3:00 AM
PR Newswire (US) The company's revolutionary, pate

US Market News

US Market News 32分前

Elite Tech, Accessible Price - Introducing the Logitech G3 Series Mouse and Keyboard for PC GamingJune 16, 2026 3:05 AM
Business Wire Elite Precision - Unleash pro-grade speed with the G305 X SUPERLIGHT gaming mouse and G316 X 98 gaming keyboard. Featur

biotechinvestor1

biotechinvestor1 35分前

You ate wrong again! Not all Halozyme targets are public info for obvious competitive reasons.
There are number of other drugs in the class of Dupixent that halozyme might have an exclusive non-disclosed contract for. Here are a few of those drugs:
Late-stage agents such as zumilokibar

US Market News

US Market News 47分前

Unilever Scales Digital Twins Across Global Manufacturing Network with AccentureJune 16, 2026 2:59 AM
Business WireUnilever (LON: ULVR) is partnering with Accenture (NYSE: ACN) to scale the use of AI-enabled digital twins across its global manufacturing network

CelestialSage6

CelestialSage6 49分前

You can't refute it. Yes, I understand your level well.

biotechinvestor1

biotechinvestor1 55分前

Total nonsense! I have no interest in educating you.

Nemesis18

Nemesis18 56分前

She'll probably move to somewhere without any extradition treaty once the plug is finally pulled on this 'cancer vaccine' scam.?

price_and_volume

price_and_volume 59分前

Gonna have to bump the A/S then...
He said recently that they are looking at another acquisition...and he will dilute with shares to get it. Agreed - I posted the same, "where's the finance coming from for acquisitions?"...

Supposed 400MM shares going to $GTVH (believe it when

Sernova Biotherapeutics

Theralase Technologies

Evolve Cloud Computing

DAXsector Pharma and Hea...

1.283% 02feb2029

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。